Annotation Detail

Information
Associated Genes
ABL1
Associated Variants
ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 )
ABL1 p.Leu406Phe (p.L406F) ( ENST00000318560.6, ENST00000372348.9 )
Associated Disease
chronic myeloid leukemia
Source Database
CIViC Evidence
Description
In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The L387F mutation in the ABL1 portion of the BCR-ABL1 fusion protein was identified and associated with resistance to nilotinib treatment (1 clone recovered at 50nM).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2863
Gene URL
https://civic.genome.wustl.edu/links/genes/4
Variant URL
https://civic.genome.wustl.edu/links/variants/1232
Rating
2
Evidence Type
Predictive
Disease
Chronic Myeloid Leukemia
Evidence Direction
Supports
Drug
Nilotinib
Evidence Level
D
Clinical Significance
Resistance
Pubmed
16772610
Drugs
Drug NameSensitivitySupported
NilotinibResitance or Non-Reponsetrue